Atossa Therapeutics announced that the United States Patent and Trademark Office has granted a new patent directed to compositions comprising endoxifen and an enteric material in which at least 90 percent of the endoxifen is (Z)-endoxifen. The patent also covers methods of administering those compositions to patients. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
- Atossa, Quantum Health announce first patient dosed first patient in I-SPY 2
- Atossa announces appointment of Parks as VP, Investor, Public Relations
- Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
- Texas probes CenterPoint, Carlyle weighs Nobian sale: Monday Buzz